For citations:
Menshikov KV, Sultanbaev AV, Musin SI, Izmailov AA, Chalov VS, Menshikova IA, Sultanbaeva NI, Popova EV, Lipatov DO. Efficacy of the 1st generation tyrosine kinase inhibitor sunitinib in the treatment of metastatic renal cell carcinoma in alternative dosing regimens. Meditsinskiy sovet = Medical Council. 2022;(9):85-92. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-9-85-92